InStride Health, an outpatient provider of specialty pediatric anxiety and OCD treatment, has raised $30 million in an oversubscribed Series B funding round. The funding was led by General Catalyst and brings the company’s total funding to $56 million.
Operating in several U.S. states, InStride accepts most major insurance plans and offers evidence-based care grounded in cognitive behavioral therapy and acceptance and commitment therapy. The company’s personalized care plans last four months to one year and have shown reductions in anxiety, functional impairment and depression for patients, as well as reductions in family accommodation and caregiver strain for parents.
The new capital will allow InStride to expand its clinical quality and reach new markets, providing insurance-based access to mental health care for children and adolescents. The company aims to further develop its supportive ecosystem by building partnerships with schools, physicians and referring providers to ensure comprehensive and collaborative care.
